1 Studies on venetoclax-resistant cell line (OCI-AML3-VenR) (Leukemia, 2022): AXL overexpression increased the IC50 of venetoclax by 4.2-fold, while AXL knockdown restored the sensitivity of cells to venetoclax;2 PDX model study (Cell Reports Medicine, 2023): The tumor inhibition rate of the combination of venetoclax and AXL inhibitor was 78%, compared with 32% of venetoclax monotherapy. This evidence concerns the gene AXL and neoplasm.